Jordyn Sava

Pembrolizumab plus lenvatinib yields clinically relevant efficacy in clear cell renal cell carcinoma subgroups based on site of metastasis and number of metastatic sites in the phase 3 CLEAR trial.

Data suggest a role for TIGIT blockade or CD25-positive cell depletion to enhance teclistamab’s efficacy in relapsed/refractory multiple myeloma.

Durvalumab plus tremelimumab in combination with neoadjuvant chemotherapy did not yield any major adverse effects in patients with newly diagnosed advanced ovarian cancer in the phase 2 KGOG3046 trial.

Lenvatinib yields survival benefit in hepatocellular carcinoma following progression on immunotherapy.

In patients with non-germinal center B cell–like diffuse large B-cell lymphoma, the combination of orelabrutinib plus R-CHOP revealed an overall response rate of 86.4%.

Abemaciclib prolonged overall survival when added to a nonsteroidal aromatase inhibitor in hormone receptor–positive, HER2–negative breast cancer, according to updated findings from the MONARCH 3 trial presented at 2022 ESMO.

Results from the phase 2 PEMMELA trial revealed positive treatment benefits in patients with malignant pleural mesothelioma who were given pembrolizumab plus lenvatinib.

Across 3 clinical trials, investigators continued to observe durable responses with larotrectinib, which showed the importance of NTRK gene fusion testing in patients with various cancer types.

Results from the phase 3 AGILE study show patients with IDH1-mutant acute myeloid leukemia had improved outcomes when treated with ivosidenib plus azacitidine vs placebo plus azacitidine.

The JAVELIN Bladder 100 trial demonstrated that avelumab plus best supportive care prolonged overall survival vs best supportive care alone for patients with advanced urothelial carcinoma.

Results of a phase 3 trial comparing neoadjuvant nivolumab plus chemotherapy denoted benefit vs chemotherapy alone for patients with resectable non-small cell lung cancer.

Children and young adults with H3K27M-positive diffuse intrinsic pontine gliomas and spinal diffuse midline gliomas saw a clinical benefit when treated with GD2-directed chimeric antigen receptor T cell therapy.